Amyloid-modifying therapies for Alzheimer's disease: Therapeutic progress and its implications

Age

Volumn 32, Issue 3, 2010, Pages 365-384

  Creed, Meaghan C ^a   Milgram, Norton W ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CanCog Technologies Incorporated   (Canada)

Author keywords

Alzheimer's disease; Amyloid cascade hypothesis; Beta amyloid; Cognition; Secretase; Vaccination

Indexed keywords

ACC 001; ADZ 103; AGENTS AFFECTING PROTEIN METABOLISM; ALPHA SECRETASE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ATORVASTATIN; BAPINEUZUMAB; BETA SECRETASE; BETA SECRETASE INHIBITOR; BMS 708163; CTS 21166; EHT 0202; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; IMMUNOGLOBULIN; LY 2811376; MEVINOLIN; PEPTIDE VACCINE; PF 04494740; PF 4494700; PLACEBO; SCYLLO INOSTOL; SEMAGACESTAT; SIMVASTATIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN VENTRICLE PERITONEUM SHUNT; CLINICAL TRIAL; DIARRHEA; DISEASE MODEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENCEPHALITIS; ENZYME INDUCTION; GASTROINTESTINAL SYMPTOM; HAIR COLOR; HEADACHE; HUMAN; MEMORY DISORDER; NAUSEA; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS;

EID: 77956182735     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-010-9142-z     Document Type: Review

References (197)

1. PA Adlard RA Cherny DI Finkelstein, et al. 2008 Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta Neuron 59 43 55 18614028
2. PS Aisen D Saumier R Briand J Laurin F Gervais P Tremblay D Garceau 2006 A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease Neurology 67 1757 1763 17082468
3. PS Aisen S Gauthier B Vellas R Briand D Saumier J Laurin D Garceau 2007 Alzhemed: a potential treatment for Alzheimer's disease Curr Alzheimer Res 4 473 478 17908052
4. O Almkvist H Basun SL Wagner BA Rowe LO Wahlund L Lannfelt 1997 Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation Arch Neurol 54 641 644 9152122
5. K Andersen LJ Launer A Ott AW Hoes MM Breteler A Hofman 1995 Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study Neurology 45 1441 1445 7644037
6. W Annaert B De Strooper 1999 Presenilins: molecular switches between proteolysis and signal transduction Trends Neurosci 22 439 443 10481190
7. Z Arvanitakis JA Schneider RS Wilson JL Bienias JF Kelly DA Evans DA Bennett 2008 Statins, incident Alzheimer disease, change in cognitive function, and neuropathology Neurology 70 1795 1802 18199831
8. CS Atwood RD Moir X Huang RC Scarpa NM Bacarra DM Romano MA Hartshorn RE Tanzi AI Bush 1998 Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis J Biol Chem 273 12817 12826 9582309
9. CS Atwood GM Bishop G Perry MA Smith 2002 Amyloid-beta: a vascular sealant that protects against hemorrhage? J Neurosci Res 70 356 12391596
10. BJ Bacskai ST Kajdasz ME McLellan D Games P Seubert D Schenk BT Hyman 2002 Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy J Neurosci 22 7873 7878 12223540
11. J Bao D Wolpowitz LW Role DA Talmage 2003 Back signaling by the Nrg-1 intracellular domain J Cell Biol 161 1133 1141 12821646
12. AJ Bayer R Bullock RW Jones D Wilkinson KR Paterson L Jenkins SB Millais S Donoghue 2005 Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD Neurology 64 94 101 15642910
13. D Beher EE Clarke JD Wrigley AC Martin A Nadin I Churcher MS Shearman 2004 Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism J Biol Chem 279 43419 43426 15304503
14. L Bertram RE Tanzi 2008 Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses Nat Rev Neurosci 9 768 778 18802446
15. D Boche E Zotova RO Weller S Love JW Neal RM Pickering D Wilkinson C Holmes JA Nicoll 2008 Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain Brain 131 3299 3310 18953056
16. DL Brody DM Holtzman 2008 Active and passive immunotherapy for neurodegenerative disorders Annu Rev Neurosci 31 175 193 18352830
17. JD Buxbaum EI Cullen LT Friedhoff 2002 Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients Front Biosci 7 a50 a59 11900994
18. H Cai Y Wang D McCarthy H Wen DR Borchelt DL Price PC Wong 2001 BACE1 is the major beta-secretase for generation of Abeta peptides by neurons Nat Neurosci 4 233 234 11224536
19. LZ Cai L Lin JS Hu ZH Zheng 2008 Effects of gamma-secretase inhibitor N-(3, 5-difluorophenacetyl-L-alanyl)-S-phenylglycine t-butyl ester on proliferation and differentiation of neural stem cells Zhonghua Yi Xue Za Zhi 88 480 483 18642791
20. CM Carlsson CE Gleason TM Hess, et al. 2008 Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease J Alzheimers Dis 13 187 197 18376061
21. RJ Castellani HG Lee X Zhu A Nunomura G Perry MA Smith 2006 Neuropathology of Alzheimer disease: pathognomonic but not pathogenic Acta Neuropathol 111 503 509 16718346
22. G Chen KS Chen D Kobayashi R Barbour R Motter D Games SJ Martin RG Morris 2007 Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid J Neurosci 27 2654 2662 17344403
23. RA Cherny CS Atwood ME Xilinas, et al. 2001 Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 665 676 11430801
24. M Citron T Oltersdorf C Haass L McConlogue AY Hung P Seubert C Vigo-Pelfrey I Lieberburg DJ Selkoe 1992 Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production Nature 360 672 674 1465129
25. F Clavaguera T Bolmont RA Crowther, et al. 2009 Transmission and spreading of tauopathy in transgenic mouse brain Nat Cell Biol 11 909 913 19503072
26. TA Comery RL Martone S Aschmies, et al. 2005 Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease J Neurosci 25 8898 8902 16192379
27. C Cornelius J Fastbom B Winblad M Viitanen 2004 Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population Neuroepidemiology 23 135 143 15084783
28. CW Cotman E Head 2008 The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches J Alzheimers Dis 15 685 707 19096165
29. CW Cotman E Head BA Muggenburg S Zicker NW Milgram 2002 Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction Neurobiol Aging 23 809 818 12392784
30. MP Cuajungco LE Goldstein A Nunomura MA Smith JT Lim CS Atwood X Huang YW Farrag G Perry AI Bush 2000 Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc J Biol Chem 275 19439 19442 10801774
31. KN Dahlgren AM Manelli WB Stine Jr LK Baker GA Krafft MJ LaDu 2002 Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability J Biol Chem 277 32046 32053 12058030
32. GR Dawson GR Seabrook H Zheng, et al. 1999 Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein Neuroscience 90 1 13 10188929
33. RB DeMattos KR Bales DJ Cummins JC Dodart SM Paul DM Holtzman 2001 Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc Natl Acad Sci U S A 98 8850 8855 11438712
34. B De Strooper 2003 Aph-1, Pen-2, and Nicastrin with presenilin generate an active gamma-secretase complex Neuron 38 9 12 12691659
35. I Dewachter D Reverse N Caluwaerts, et al. 2002 Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice J Neurosci 22 3445 3453 11978821
36. DW Dickson HA Crystal LA Mattiace DM Masur AD Blau P Davies SH Yen MK Aronson 1992 Identification of normal and pathological aging in prospectively studied nondemented elderly humans Neurobiol Aging 13 179 189 1311804
37. RC Dodel Y Du C Depboylu, et al. 2004 Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease J Neurol Neurosurg Psychiatry 75 1472 1474 15377700
38. HF Dovey V John JP Anderson, et al. 2001 Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain J Neurochem 76 173 181 11145990
39. J Drake CD Link DA Butterfield 2003 Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model Neurobiol Aging 24 415 420 12600717
40. Y Du X Wei R Dodel N Sommer H Hampel F Gao Z Ma L Zhao WH Oertel M Farlow 2003 Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity Brain 126 1935 1939 12821522
41. S Du Yan H Zhu J Fu SF Yan A Roher WW Tourtellotte T Rajavashisth X Chen GC Godman D Stern AM Schmidt 1997 Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease Proc Natl Acad Sci U S A 94 5296 5301 9144231
42. H Englund M Degerman Gunnarsson RM Brundin M Hedlund L Kilander L Lannfelt FE Pettersson 2009 Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid Neurodegener Dis 6 139 147 19521063
43. JL Eriksen SA Sagi TE Smith S Weggen P Das DC McLendon VV Ozols KW Jessing KH Zavitz EH Koo TE Golde 2003 NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo J Clin Invest 112 440 449 12897211
44. SA Farber RM Nitsch JG Schulz RJ Wurtman 1995 Regulated secretion of beta-amyloid precursor protein in rat brain J Neurosci 15 7442 7451 7472496
45. K Fassbender M Simons C Bergmann, et al. 2001 Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo Proc Natl Acad Sci U S A 98 5856 5861 11296263
46. I Ferrer M Boada Rovira ML Sanchez Guerra MJ Rey F Costa-Jussa 2004 Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease Brain Pathol 14 11 20 14997933
47. AS Fleisher R Raman ER Siemers, et al. 2008 Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol 65 1031 1038 18695053
48. LT Friedhoff EI Cullen NS Geoghagen JD Buxbaum 2001 Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide Int J Neuropsychopharmacol 4 127 130 11466161
49. DR Galasko N Graff-Radford S May, et al. 2007 Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals Alzheimer Dis Assoc Disord 21 292 299 18090435
50. F Gervais J Paquette C Morissette, et al. 2007 Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis Neurobiol Aging 28 537 547 16675063
51. AK Ghosh N Kumaragurubaran L Hong, et al. 2008 Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation Bioorg Med Chem Lett 18 1031 1036 18180160
52. S Gilman M Koller RS Black L Jenkins SG Griffith NC Fox L Eisner L Kirby MB Rovira F Forette JM Orgogozo 2005 Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 1553 1562 15883316
53. A Goate MC Chartier-Harlin M Mullan J Brown F Crawford L Fidani L Giuffra A Haynes N Irving L James, et al. 1991 Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease Nature 349 704 706 1671712
54. EJ Golob GG Miranda JK Johnson A Starr 2001 Sensory cortical interactions in aging, mild cognitive impairment, and Alzheimer's disease Neurobiol Aging 22 755 763 11705635
55. F Gounari R Chang J Cowan Z Guo M Dose E Gounaris K Khazaie 2005 Loss of adenomatous polyposis coli gene function disrupts thymic development Nat Immunol 6 800 809 16025118
56. AR Group CG Lyketsos JC Breitner RC Green BK Martin C Meinert S Piantadosi M Sabbagh 2007 Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology 68 1800 1808
57. Z Gu P Zhong Z Yan 2003 Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices J Biol Chem 278 17546 17556 12606559
58. MD Haag A Hofman PJ Koudstaal BH Stricker MM Breteler 2009 Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study J Neurol Neurosurg Psychiatry 80 13 17 18931004
59. J Hardy D Allsop 1991 Amyloid deposition as the central event in the aetiology of Alzheimer's disease Trends Pharmacol Sci 12 383 388 1763432
60. E Head R Torp 2002 Insights into Abeta and presenilin from a canine model of human brain aging Neurobiol Dis 9 1 10 11848680
61. SS Hebert L Serneels T Dejaegere K Horre M Dabrowski V Baert W Annaert D Hartmann B De Strooper 2004 Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity Neurobiol Dis 17 260 272 15474363
62. DB Henley PC May RA Dean ER Siemers 2009 Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease Expert Opin Pharmacother 10 1657 1664 19527190
63. K Hoglund KM Thelen S Syversen M Sjogren K von Bergmann A Wallin E Vanmechelen H Vanderstichele D Lutjohann K Blennow 2005 The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease Dement Geriatr Cogn Disord 19 256 265 15785028
64. C Holmes D Boche D Wilkinson, et al. 2008 Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 216 223 18640458
65. X Hu CW Hicks W He P Wong WB Macklin BD Trapp R Yan 2006 Bace1 modulates myelination in the central and peripheral nervous system Nat Neurosci 9 1520 1525 17099708
66. X Hu W He C Diaconu X Tang GJ Kidd WB Macklin BD Trapp R Yan 2008 Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves FASEB J 22 2970 2980 18413858
67. X Huang CS Atwood RD Moir MA Hartshorn RE Tanzi AI Bush 2004 Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides J Biol Inorg Chem 9 954 960 15578276
68. LA Hyde NA McHugh J Chen, et al. 2006 Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3, 5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-di hydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide (LY411, 575) in the CRND8 mouse J Pharmacol Exp Ther 319 1133 1143 16946102
69. Imbimbo BP (2009) Why did tarenflurbil fail in Alzheimer's disease? J Alzheimers Dis 17(4):757-760
70. BA in 't Veld LJ Launer AW Hoes A Ott A Hofman MM Breteler BH Stricker 1998 NSAIDs and incident Alzheimer's disease. The Rotterdam Study Neurobiol Aging 19 607 611 10192221
71. G Istrin E Bosis B Solomon 2006 Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide J Neurosci Res 84 434 443 16767774
72. C Janus J Pearson J McLaurin, et al. 2000 A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 979 982 11140685
73. J Joseph B Shukitt-Hale NA Denisova A Martin G Perry MA Smith 2001 Copernicus revisited: amyloid beta in Alzheimer's disease Neurobiol Aging 22 131 146 11164287
74. RW Jones M Kivipelto H Feldman L Sparks R Doody DD Waters J Hey-Hadavi A Breazna RJ Schindler H Ramos LEADe investigators 2008 The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics Alzheimers Dement 4 2 145 153 18631958
75. F Kamenetz T Tomita H Hsieh G Seabrook D Borchelt T Iwatsubo S Sisodia R Malinow 2003 APP processing and synaptic function Neuron 37 925 937 12670422
76. DY Kim LA Ingano BW Carey WH Pettingell DM Kovacs 2005 Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration J Biol Chem 280 23251 23261 15833746
77. H Kokubo R Kayed CG Glabe TC Saido N Iwata JB Helms H Yamaguchi 2005 Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain Brain Res 1045 224 228 15910781
78. U Kovacic J Sketelj FF Bajrovic 2009 Chapter 26: Age-related differences in the reinnervation after peripheral nerve injury Int Rev Neurobiol 87 465 482 19682655
79. S Kumar-Singh J Theuns B Van Broeck D Pirici K Vennekens E Corsmit M Cruts B Dermaut R Wang C Van Broeckhoven 2006 Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40 Hum Mutat 27 686 695 16752394
80. PN Lacor MC Buniel L Chang, et al. 2004 Synaptic targeting by Alzheimer's-related amyloid beta oligomers J Neurosci 24 10191 10200 15537891
81. PN Lacor MC Buniel PW Furlow AS Clemente PT Velasco M Wood KL Viola WL Klein 2007 Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease J Neurosci 27 796 807 17251419
82. L Lannfelt K Blennow H Zetterberg, et al. 2008 Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 779 786 18672400
83. TA Lanz CS Himes G Pallante L Adams S Yamazaki B Amore KM Merchant 2003 The gamma-secretase inhibitor N-[N-(3, 5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice J Pharmacol Exp Ther 305 864 871 12626636
84. TL Lau EE Ambroggio DJ Tew R Cappai CL Masters GD Fidelio KJ Barnham F Separovic 2006 Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions J Mol Biol 356 759 770 16403524
85. JY Lee JE Friedman I Angel A Kozak JY Koh 2004 The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice Neurobiol Aging 25 1315 1321 15465629
86. HG Lee X Zhu A Nunomura G Perry MA Smith 2006 Amyloid beta: the alternate hypothesis Curr Alzheimer Res 3 75 80 16472207
87. CA Lemere M Maier L Jiang Y Peng TJ Seabrook 2006 Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans Rejuvenation Res 9 77 84 16608400
88. E Levy-Lahad W Wasco P Poorkaj DM Romano J Oshima WH Pettingell CE Yu PD Jondro SD Schmidt K Wang, et al. 1995 Candidate gene for the chromosome 1 familial Alzheimer's disease locus Science 269 973 977 7638622
89. J Lewis DW Dickson WL Lin, et al. 2001 Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP Science 293 1487 1491 11520987
90. SF Lichtenthaler DI Dominguez GG Westmeyer K Reiss C Haass P Saftig B De Strooper B Seed 2003 The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1 J Biol Chem 278 48713 48719 14507929
91. Y Liu DA Peterson D Schubert 1998 Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis Proc Natl Acad Sci U S A 95 13266 13271 9789077
92. A Louvi S Artavanis-Tsakonas 2006 Notch signalling in vertebrate neural development Nat Rev Neurosci 7 93 102 16429119
93. PR Louzada AC Paula Lima DL Mendonca-Silva F Noel FG De Mello ST Ferreira 2004 Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders FASEB J 18 511 518 15003996
94. Y Luo B Bolon S Kahn, et al. 2001 Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation Nat Neurosci 4 231 232 11224535
95. JB Mackic M Stins JG McComb M Calero J Ghiso KS Kim SD Yan D Stern AM Schmidt B Frangione BV Zlokovic 1998 Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer J Clin Invest 102 734 743 9710442
96. F Magara U Muller ZW Li HP Lipp C Weissmann M Stagljar DP Wolfer 1999 Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing the beta-amyloid-precursor protein Proc Natl Acad Sci U S A 96 4656 4661 10200318
97. M Marcade J Bourdin N Loiseau H Peillon A Rayer D Drouin F Schweighoffer L Desire 2008 Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing J Neurochem 106 392 404 18397369
98. E Marcello F Gardoni D Mauceri S Romorini A Jeromin R Epis B Borroni F Cattabeni C Sala A Padovani M Di Luca 2007 Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity J Neurosci 27 1682 1691 17301176
99. RJ Mark JW Ashford Y Goodman MP Mattson 1995 Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology Neurobiol Aging 16 187 198 7777136
100. E Masliah L Hansen A Adame L Crews F Bard C Lee P Seubert D Games L Kirby D Schenk 2005 Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 64 129 131 15642916
101. A Mathie GL Sutton CE Clarke EL Veale 2006 Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability Pharmacol Ther 111 567 583 16410023
102. MP Mattson MG Engle B Rychlik 1991 Effects of elevated intracellular calcium levels on the cytoskeleton and tau in cultured human cortical neurons Mol Chem Neuropathol 15 117 142 1663746
103. E McGowan J Eriksen M Hutton 2006 A decade of modeling Alzheimer's disease in transgenic mice Trends Genet 22 281 289 16567017
104. J McLaurin T Franklin A Chakrabartty PE Fraser 1998 Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest J Mol Biol 278 183 194 9571042
105. J McLaurin R Golomb A Jurewicz JP Antel PE Fraser 2000 Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity J Biol Chem 275 18495 18502 10764800
106. J McLaurin ME Kierstead ME Brown, et al. 2006 Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model Nat Med 12 801 808 16767098
107. L Mei WC Xiong 2008 Neuregulin 1 in neural development, synaptic plasticity and schizophrenia Nat Rev Neurosci 9 437 452 18478032
108. J Milano J McKay C Dagenais L Foster-Brown F Pognan R Gadient RT Jacobs A Zacco B Greenberg PJ Ciaccio 2004 Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation Toxicol Sci 82 341 358 15319485
109. MC Miller R Tavares CE Johanson V Hovanesian JE Donahue L Gonzalez GD Silverberg EG Stopa 2008 Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease Brain Res 1230 273 280 18657529
110. H Mohmmad Abdul GL Wenk M Gramling B Hauss-Wegrzyniak DA Butterfield 2004 APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease Neurosci Lett 368 148 150 15351438
111. H Mohmmad Abdul R Sultana JN Keller DK St Clair WR Markesbery DA Butterfield 2006 Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease J Neurochem 96 1322 1335 16478525
112. D Morgan DM Diamond PE Gottschall, et al. 2000 A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 982 985 11140686
113. U Muller N Cristina ZW Li DP Wolfer HP Lipp T Rulicke S Brandner A Aguzzi C Weissmann 1994 Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene Cell 79 755 765 8001115
114. T Nakagawa H Zhu N Morishima E Li J Xu BA Yankner J Yuan 2000 Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta Nature 403 98 103 10638761
115. M Nakamura N Shishido A Nunomura MA Smith G Perry Y Hayashi K Nakayama T Hayashi 2007 Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron Biochemistry 46 12737 12743 17929832
116. JA Nicoll D Wilkinson C Holmes P Steart H Markham RO Weller 2003 Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report Nat Med 9 448 452 12640446
117. JA Nicoll E Barton D Boche, et al. 2006 Abeta species removal after abeta42 immunization J Neuropathol Exp Neurol 65 1040 1048 17086100
118. A Nikolaev T McLaughlin DD O'Leary M Tessier-Lavigne 2009 APP binds DR6 to trigger axon pruning and neuron death via distinct caspases Nature 457 981 989 19225519
119. M Nistor M Don M Parekh, et al. 2007 Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain Neurobiol Aging 28 1493 1506 16904243
120. RM Nitsch JH Growdon 1994 Role of neurotransmission in the regulation of amyloid beta-protein precursor processing Biochem Pharmacol 47 1275 1284 7910457
121. RM Nitsch SA Farber JH Growdon RJ Wurtman 1993 Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices Proc Natl Acad Sci U S A 90 5191 5193 8506366
122. A Nunomura G Perry MA Pappolla R Wade K Hirai S Chiba MA Smith 1999 RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease J Neurosci 19 1959 1964 10066249
123. A Nunomura G Perry MA Pappolla RP Friedland K Hirai S Chiba MA Smith 2000 Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome J Neuropathol Exp Neurol 59 1011 1017 11089579
124. A Nunomura G Perry G Aliev, et al. 2001 Oxidative damage is the earliest event in Alzheimer disease J Neuropathol Exp Neurol 60 759 767 11487050
125. A Nunomura S Chiba CF Lippa P Cras RN Kalaria A Takeda K Honda MA Smith G Perry 2004 Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease Neurobiol Dis 17 108 113 15350971
126. S Oddo A Caccamo L Tran MP Lambert CG Glabe WL Klein FM LaFerla 2006 Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology J Biol Chem 281 1599 1604 16282321
127. M Ohno EA Sametsky LH Younkin H Oakley SG Younkin M Citron R Vassar JF Disterhoft 2004 BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease Neuron 41 27 33 14715132
128. M Ohno L Chang W Tseng H Oakley M Citron WL Klein R Vassar JF Disterhoft 2006 Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1 Eur J Neurosci 23 251 260 16420434
129. M Okochi A Fukumori J Jiang N Itoh R Kimura H Steiner C Haass S Tagami M Takeda 2006 Secretion of the Notch-1 Abeta-like peptide during Notch signaling J Biol Chem 281 7890 7898 16434391
130. RE Olson CF Albright 2008 Recent progress in the medicinal chemistry of gamma-secretase inhibitors Curr Top Med Chem 8 17 33 18220929
131. JM Orgogozo S Gilman JF Dartigues, et al. 2003 Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 46 54 12847155
132. N Papaioannou PC Tooten AM van Ederen JR Bohl J Rofina T Tsangaris E Gruys 2001 Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques Amyloid 8 11 21 11293821
133. P Pasqualetti C Bonomini G Dal Forno L Paulon E Sinforiani C Marra O Zanetti PM Rossini 2009 A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease Aging Clin Exp Res 21 102 110 19448381
134. RL Patton WM Kalback CL Esh, et al. 2006 Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis Am J Pathol 169 1048 1063 16936277
135. AC Paula-Lima PR Louzada FG De Mello ST Ferreira 2003 Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox Res 5 323 327 14715451
136. JU Peters G Galley H Jacobsen C Czech P David-Pierson EA Kitas L Ozmen 2007 Novel orally active, dibenzazepinone-based gamma-secretase inhibitors Bioorg Med Chem Lett 17 5918 5923 17869099
137. R Pluta M Oseka S Januszewski A Misicka AW Lipkowski M Barcikowska E Kozniewska 1996 Increase of cerebral blood flow in rats after human b-amyloid peptide infusion Folia Morphol (Warsz) 55 420 421
138. R Postina A Schroeder I Dewachter, et al. 2004 A disintegrin- metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model J Clin Invest 113 1456 1464 15146243
139. F Radtke A Wilson G Stark M Bauer J van Meerwijk HR MacDonald M Aguet 1999 Deficient T cell fate specification in mice with an induced inactivation of Notch1 Immunity 10 547 558 10367900
140. CW Ritchie AI Bush A Mackinnon, et al. 2003 Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial Arch Neurol 60 1685 1691 14676042
141. SL Roberds J Anderson G Basi, et al. 2001 BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics Hum Mol Genet 10 1317 1324 11406613
142. CA Rottkamp AK Raina X Zhu E Gaier AI Bush CS Atwood M Chevion G Perry MA Smith 2001 Redox-active iron mediates amyloid-beta toxicity Free Radic Biol Med 30 447 450 11182300
143. JM Ryan M Grundman 2009 Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing J Alzheimers Dis 17 243 19502708
144. S Sakurai H Yonekura Y Yamamoto T Watanabe N Tanaka H Li AK Rahman KM Myint CH Kim H Yamamoto 2003 The AGE-RAGE system and diabetic nephropathy J Am Soc Nephrol 14 S259 S263 12874443
145. S Salloway R Sperling S Gilman, et al. 2009 A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2061 2070 19923550
146. AR Sandy I Maillard 2009 Notch signaling in the hematopoietic system Expert Opin Biol Ther 9 1383 1398 19743891
147. I Santa-Maria F Hernandez J Del Rio FJ Moreno J Avila 2007 Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau Mol Neurodegener 2 17 17822548
148. CA Saura SY Choi V Beglopoulos, et al. 2004 Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration Neuron 42 23 36 15066262
149. CA Saura G Chen S Malkani SY Choi RH Takahashi D Zhang GK Gouras A Kirkwood RG Morris J Shen 2005 Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice J Neurosci 25 6755 6764 16033885
150. D Schenk R Barbour W Dunn, et al. 1999 Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 173 177 10408445
151. DB Schenk P Seubert I Lieberburg J Wallace 2000 Beta-peptide immunization: a possible new treatment for Alzheimer disease Arch Neurol 57 7 934 936 10891974
152. GR Seabrook WJ Ray M Shearman M Hutton 2007 Beyond amyloid: the next generation of Alzheimer's disease therapeutics Mol Interv 7 261 270 17932415
153. DJ Selkoe 1996 Amyloid beta-protein and the genetics of Alzheimer's disease J Biol Chem 271 18295 18298 8756120
154. K Sennvik J Fastbom M Blomberg LO Wahlund B Winblad E Benedikz 2000 Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients Neurosci Lett 278 169 172 10653020
155. L Serneels J Van Biervliet K Craessaerts, et al. 2009 Gamma-secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease Science 324 639 642 19299585
156. LM Shaw H Vanderstichele M Knapik-Czajka, et al. 2009 Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 403 413 19296504
157. R Sherrington EI Rogaev Y Liang EA Rogaeva G Levesque M Ikeda H Chi C Lin G Li K Holman, et al. 1995 Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease Nature 375 754 760 7596406
158. K Shirotani D Edbauer S Prokop C Haass H Steiner 2004 Identification of distinct gamma-secretase complexes with different APH-1 variants J Biol Chem 279 41340 41345 15286082
159. ER Siemers JF Quinn J Kaye, et al. 2006 Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease Neurology 66 602 604 16505324
160. ER Siemers RA Dean S Friedrich L Ferguson-Sells C Gonzales MR Farlow PC May 2007 Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase Clin Neuropharmacol 30 317 325 18090456
161. EM Sigurdsson H Scholtzova PD Mehta B Frangione T Wisniewski 2001 Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice Am J Pathol 159 439 447 11485902
162. GD Silverberg E Levinthal EV Sullivan, et al. 2002 Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study Neurology 59 1139 1145 12391340
163. GD Silverberg M Mayo T Saul J Carvalho D McGuire 2004 Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers Expert Rev Neurother 4 97 107 15853620
164. GD Silverberg M Mayo T Saul J Fellmann J Carvalho D McGuire 2008 Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study Neurology 71 202 209 18525029
165. SA Small K Duff 2008 Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis Neuron 60 534 542 19038212
166. DL Sparks DJ Connor PJ Browne JE Lopez MN Sabbagh 2002 HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier J Nutr Health Aging 6 324 331 12474023
167. DL Sparks MN Sabbagh DJ Connor J Lopez LJ Launer P Browne D Wasser S Johnson-Traver J Lochhead C Ziolwolski 2005 Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results Arch Neurol 62 753 757 15883262
168. DL Sparks RJ Kryscio MN Sabbagh DJ Connor LM Sparks C Liebsack 2008 Reduced risk of incident AD with elective statin use in a clinical trial cohort Curr Alzheimer Res 5 416 421 18690839
169. PA Stewart K Hayakawa MA Akers HV Vinters 1992 A morphometric study of the blood-brain barrier in Alzheimer's disease Lab Invest 67 734 742 1460864
170. Strobel G (2008) Chicago: Bapineuzumab's Phase 2-was the data better than the spin? http://www.alzforum.org/new/detail.asp?id=1894 (accessed September 2009).
171. E Sturchler A Galichet M Weibel E Leclerc CW Heizmann 2008 Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity J Neurosci 28 5149 5158 18480271
172. A Takashima T Honda K Yasutake G Michel O Murayama M Murayama K Ishiguro H Yamaguchi 1998 Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons Neurosci Res 31 317 323 9809590
173. T Tokuda A Tamaoka S Matsuno S Sakurai H Shimada H Morita S Ikeda 2001 Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins Ann Neurol 49 546 547 11310640
174. M Townsend JP Cleary T Mehta J Hofmeister S Lesne E O'Hare DM Walsh DJ Selkoe 2006 Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers Ann Neurol 60 668 676 17192927
175. PR Turner K O'Connor WP Tate WC Abraham 2003 Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory Prog Neurobiol 70 1 32 12927332
176. IH Ulus RJ Wurtman 1997 Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices J Pharmacol Exp Ther 281 149 154 9103492
177. V Vasilevko E Head 2009 Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle CNS Neurol Disord Drug Targets 8 98 113 19355931
178. B Vellas R Black LJ Thal NC Fox M Daniels G McLennan C Tompkins C Leibman M Pomfret M Grundman 2009 Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders Curr Alzheimer Res 6 144 151 19355849
179. KL Viola PT Velasco WL Klein 2008 Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs) J Nutr Health Aging 12 51S 57S 18165846
180. CS von Koch H Zheng H Chen M Trumbauer G Thinakaran LH van der Ploeg DL Price SS Sisodia 1997 Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice Neurobiol Aging 18 661 669
181. LC Walker CA Kitt RG Struble MV Wagster DL Price LC Cork 1988 The neural basis of memory decline in aged monkeys Neurobiol Aging 9 657 666 3145465
182. S Weggen JL Eriksen SA Sagi CU Pietrzik TE Golde EH Koo 2003 Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain J Biol Chem 278 30748 30754 12777371
183. S Weggen JL Eriksen SA Sagi CU Pietrzik V Ozols A Fauq TE Golde EH Koo 2003 Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity J Biol Chem 278 31831 31837 12805356
184. JH Weiss DM Hartley JY Koh DW Choi 1993 AMPA receptor activation potentiates zinc neurotoxicity Neuron 10 43 49 7678965
185. GK Wilcock 2010 Bapineuzumab in Alzheimer's disease: where now? Lancet Neurol 9 134 136 20129159
186. GK Wilcock SE Black SB Hendrix KH Zavitz EA Swabb MA Laughlin 2008 Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial Lancet Neurol 7 483 493 18450517
187. MS Wolfe W Xia BL Ostaszewski TS Diehl WT Kimberly DJ Selkoe 1999 Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity Nature 398 513 517 10206644
188. HK Wong T Sakurai F Oyama K Kaneko K Wada H Miyazaki M Kurosawa B De Strooper P Saftig N Nukina 2005 beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase J Biol Chem 280 23009 23017 15824102
189. SD Yan SF Yan X Chen J Fu M Chen P Kuppusamy MA Smith G Perry GC Godman P Nawroth, et al. 1995 Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide Nat Med 1 693 699 7585153
190. M Yokoyama J Koh DW Choi 1986 Brief exposure to zinc is toxic to cortical neurons Neurosci Lett 71 351 355 3796893
191. H Yu CA Saura SY Choi, et al. 2001 APP processing and synaptic plasticity in presenilin-1 conditional knockout mice Neuron 31 713 726 11567612
192. E Zamrini G McGwin JM Roseman 2004 Association between statin use and Alzheimer's disease Neuroepidemiology 23 94 98 14739574
193. M Zaudig 1992 A new systematic method of measurement and diagnosis of "mild cognitive impairment" and dementia according to ICD-10 and DSM-III-R criteria Int Psychogeriatr 4 Suppl 2 203 219 1288663
194. C Zhang B Wu V Beglopoulos M Wines-Samuelson D Zhang I Dragatsis TC Sudhof J Shen 2009 Presenilins are essential for regulating neurotransmitter release Nature 460 632 636 19641596
195. H Zheng M Jiang ME Trumbauer, et al. 1995 Beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity Cell 81 525 531 7758106
196. WH Zheng S Bastianetto F Mennicken W Ma S Kar 2002 Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures Neuroscience 115 201 211 12401334
197. BV Zlokovic 2004 Clearing amyloid through the blood-brain barrier J Neurochem 89 807 811 15140180